![CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure – CEPI CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure – CEPI](https://cepi.net/wp-content/uploads/2020/11/IMAGE-CLOVER-EXPANDED-PARTNERSHIP.jpg)
CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure – CEPI
![China's Clover generates US$230m in funding as its COVID-19 vaccine candidate edges towards late stage clinical trial China's Clover generates US$230m in funding as its COVID-19 vaccine candidate edges towards late stage clinical trial](https://www.biopharma-reporter.com/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/pharmaceutical-science/biopharma-reporter.com/headlines/markets-regulations/china-s-clover-generates-us-230m-in-funding-as-its-covid-19-vaccine-candidate-edges-towards-late-stage-clinical-trial/12215287-1-eng-GB/China-s-Clover-generates-US-230m-in-funding-as-its-COVID-19-vaccine-candidate-edges-towards-late-stage-clinical-trial.jpg)
China's Clover generates US$230m in funding as its COVID-19 vaccine candidate edges towards late stage clinical trial
![Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest](https://mma.prnewswire.com/media/1631948/Clover_s_Manufacturing_Facility_in_Changxing_China.jpg?p=facebook)
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
![Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern](https://mma.prnewswire.com/media/1430121/Clover_logo.jpg?p=facebook)
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
![Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern](https://mma.prnewswire.com/media/1430121/Clover_logo.jpg?p=twitter)
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
![Drug Discovery News on Twitter: "#Dynavax to provide #TLR9 agonist #adjuvant CpG 1018 to help #Clover #Biopharma evaluate its #COVID19 #vaccine lead #Coronavirus S-trimer subunit vaccine developed using Clover's Trimer-Tag platform https://t.co ... Drug Discovery News on Twitter: "#Dynavax to provide #TLR9 agonist #adjuvant CpG 1018 to help #Clover #Biopharma evaluate its #COVID19 #vaccine lead #Coronavirus S-trimer subunit vaccine developed using Clover's Trimer-Tag platform https://t.co ...](https://pbs.twimg.com/media/ET4yXn1WAAAfEw4.jpg)
Drug Discovery News on Twitter: "#Dynavax to provide #TLR9 agonist #adjuvant CpG 1018 to help #Clover #Biopharma evaluate its #COVID19 #vaccine lead #Coronavirus S-trimer subunit vaccine developed using Clover's Trimer-Tag platform https://t.co ...
![S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-21634-1/MediaObjects/41467_2021_21634_Fig1_HTML.png)
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
![Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e4d685d1-d8cb-46ba-b991-1ea92c581902/gr1_lrg.jpg)
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
![CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals' Australian Subsidiary - Clover Biopharmaceuticals CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals' Australian Subsidiary - Clover Biopharmaceuticals](http://www.cloverbiopharma.com/upload/news/20200427060402543.png)
CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals' Australian Subsidiary - Clover Biopharmaceuticals
![Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate](https://mma.prnewswire.com/media/1430155/CLOVER_DYNAVAX_Logo.jpg?p=facebook)
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
![Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China | Business Wire Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China | Business Wire](https://mms.businesswire.com/media/20190507005611/en/720254/23/Clover-Logo-ENGLISH.jpg)
Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China | Business Wire
Fierce Pharma Asia—WuXi-BMS plant deal; Clover-GSK COVID-19 vax pact ends; Illumina-Sequoia genomics incubator | Fierce Pharma
![CEPI expands partnership with Clover Biopharmaceuticals to rapidly advance development and manufacture of COVID-19 vaccine candidate – CEPI CEPI expands partnership with Clover Biopharmaceuticals to rapidly advance development and manufacture of COVID-19 vaccine candidate – CEPI](https://cepi.net/wp-content/uploads/2020/07/20200426012618258-scaled.jpg)
CEPI expands partnership with Clover Biopharmaceuticals to rapidly advance development and manufacture of COVID-19 vaccine candidate – CEPI
![Magnetic and trimer order parameters. a "Clover-leaf" structural domain... | Download Scientific Diagram Magnetic and trimer order parameters. a "Clover-leaf" structural domain... | Download Scientific Diagram](https://www.researchgate.net/profile/Hena-Das/publication/259587460/figure/fig10/AS:667058274578442@1536050494479/Magnetic-and-trimer-order-parameters-a-Clover-leaf-structural-domain-pattern-where.png)
Magnetic and trimer order parameters. a "Clover-leaf" structural domain... | Download Scientific Diagram
![Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/32b4f7f5-a2ff-459c-9431-ea13860d3d0f/gr3_lrg.jpg)
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
![Clover Biopharmaceuticals Becomes the 9th Enterprise in CDHT Listed on the Hong Kong Stock Exchange_News_GaoxinEnglish Clover Biopharmaceuticals Becomes the 9th Enterprise in CDHT Listed on the Hong Kong Stock Exchange_News_GaoxinEnglish](http://www.cdht.gov.cn/gaoxin/c141902/2021-12/20/edd6142c27ac45289add7fcc8092cf5c/images/d3c498cd9ebe4768b03dc70ed679cd6c.jpg)
Clover Biopharmaceuticals Becomes the 9th Enterprise in CDHT Listed on the Hong Kong Stock Exchange_News_GaoxinEnglish
![S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-021-21634-1/MediaObjects/41467_2021_21634_Fig5_HTML.png)